4-fluoro-N-[4-[4-(2-methoxyethoxy)phenyl]pyrimidin-2-yl]-N-(3-methyl-1-azabicyclo[2.2.2]octan-3-yl)piperidine-4-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-fluoro-N-[4-[4-(2-methoxyethoxy)phenyl]pyrimidin-2-yl]-N-(3-methyl-1-azabicyclo[2.2.2]octan-3-yl)piperidine-4-carboxamide
• 化学式: C₂₇H₃₆FN₅O₃
• 分子量: 497.6
• InChiKey: MPQLBJGHZBOXQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  36
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  79.8
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• [EN] GLUCOSYLCERAMIDE SYNTHASE INHIBITORS<br/>[FR] INHIBITEURS DE SYNTHASE DE GLUCOSYLCÉRAMIDE
  申请人：GENZYME CORP

  公开号：WO2014043068A1

  公开（公告）日：2014-03-20

  The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.

  该发明涉及抑制葡萄糖鞘氨醇合成酶（GCS）的抑制剂，用于治疗代谢性疾病，如溶酶体贮积病，单独或与酶替代疗法、囊性疾病以及癌症的联合治疗。
• GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
  申请人：Genzyme Corporation

  公开号：EP2895484A1

  公开（公告）日：2015-07-22
• BIOMARKERS OF POLYCYSTIC KIDNEY DISEASE AND USES THEREOF
  申请人：Genzyme Corporation

  公开号：EP3177932A2

  公开（公告）日：2017-06-14
• BIOMARKER OF POLYCYSTIC KIDNEY DISEASE AND USES THEREOF
  申请人：Genzyme Corporation

  公开号：EP3377908A1

  公开（公告）日：2018-09-26
• [EN] BIOMARKERS OF POLYCYSTIC KIDNEY DISEASE AND USES THEREOF<br/>[FR] BIOMARQUEURS DE MALADIE POLYKYSTIQUE DES REINS ET UTILISATIONS ASSOCIÉES
  申请人：GENZYME CORP

  公开号：WO2016022500A2

  公开（公告）日：2016-02-11

  Provided herein are methods for determining the efficacy of treatment for polycystic kidney disease (PKD) in a patient, diagnosing PKD in a patient, staging PKD in a patient, and monitoring PKD in a patient. These methods include determining a single or multiple levels of one or more markers selected from the group of Proliferating Cell Nuclear Antigen (PCNA), cyclin D1, cyclin D3, MAPKERK kinase 1 (MEK), ribosomal protein S6 (S6), phosphorylated ribosomal protein S6 (pS6), extracellular signal-regulated kinase (ERK), phosphorylated extracellular signal-regulated kinase (pERK), protein kinase B (Akt), phosphorylated protein kinase B (pAkt), caspase-2, total S6, and retinoblastoma binding protein (RBBP). Also provided are kits that include at least three antibodies that specifically bind to one or more of these markers.